DOI: https://doi.org/10.22141/2224-0713.3.81.2016.77615

Laboratory Biomarkers of Early Diagnosis of Parkinson’s Disease

V.V. Ponomariov, O.V. Boiko, O.O. Ionova

Abstract


The article contains a review data on the current laboratory diagnosis of Parkinson’s disease. The results on the informativity of determining alpha-synuclein, DJ‑1, biomarkers of oxidative stress, neurotransmitters, neurotoxins, specific antibodies, tau protein in different biological environments of the human body systems are provided. There are presented the of authors’ own researches. The prospects of further development of this approach in the study of Parkinson’s disease are shown.


Keywords


Parkinson’s disease; laboratory diagnostics; biomarkers

References


Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., Marek K. Levodopa and the progression of Parkinson’s disease // N. Engl. J. Med. 2004; 351(2): 2498-2508.

Wu Y., Le W., Jankovic J. Preclinical Biomarkers of Parkinson Disease // Arch. Neurol. 2011; 68(4): 22-30.

Lama M., Chahine B., Matthew B. Stern Diagnostic markers for Parkinson’s disease // Curr. Opin. Neurol. 2011; 24(3): 309-317.

Saracchi E., Fermi S., Brighina L. Emerging Candidate Biomarkers for Parkinson’s Disease: a Review // Aging and Disease. 2013; 5(6): 27-34.

El-Agnaf O.M., Salem S.A., Paleologou K.E., Cooper L.J., Fullwood N.J., Gibson M.J., Curran M.D., Court J.A., Mann D.M., Ikeda S., Cookson M.R., Hardy J., Allsop D. Alpha-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma // FASEB J. 2003; 17(5): 1945-1947.

Devic I., Hwang H., Edgar J.S., Izutsu K., Presland R., Pan C., Goodlett D.R., Wang Y., Armaly J., Tumas V., Zabetian C.P., Leverenz J.B., Shi M., Zhang J. Salivary α-synuclein and DJ‑1: potential biomarkers for Parkinson’s disease // Brain. 2011; 134(5): 178-183.

El-Agnaf O.M., Salem S.A., Paleologou K.E., Curran M.D., Gibson M.J., Court J.A., Schlossmacher M.G., Allsop D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease // FASEB J. 2006; 20(7): 419-425.

Foulds P.G., Mitchell J.D., Parker A., Turner R., Green G., Diggle P., Hasegawa M., Taylor M., Mann D., Allsop D. Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson’s disease // FASEB J. 2011; 25(4): 4127-4137.

Prigione A., Piazza F., Brighina L., Begni B., Galbussera A., Difrancesco J.C., Andreoni S., Piolti R., Ferrarese C. Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease // Neurosci. Lett. 2010; 477(8): 6-10.

Puschmann A. Monogenic Parkinson’s d isease and parkinsonism: clinical phenotypes and frequencies of known mutations // Parkinsonism Relat. Disord. 2013; 19(6): 407-415.

Shi M., Zabetian C.P., Hancock A.M., Ginghina C., Hong Z., Yearout D., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Leverenz J.B., Zhang J. Significance and confounders of peripheral DJ‑1 and alpha-synuclein in Parkinson’s disease // Neurosci. Lett. 2010; 480(5): 78-82.

Lin X., Cook T.J., Zabetian C.P., Leverenz J.B., Peskind E.R., Hu S.C., Cain K.C., Pan C., Edgar J.S., Goodlett D.R., Racette B.A., Checkoway H., Montine T.J., Shi M., Zhang J. DJ‑1 isoforms in whole blood as potential biomarkers of Parkinson disease // Sci. Rep. 2012; 2(7): 954-967.

Han M., Nagele E., DeMarshall C., Acharya N., Nagele R. Diagnosis of Parkinson’s disease based on disease-specific autoantibody profiles in human sera // PloS ONE. 2012; 7(2): 323-383.

Levin E.C., Acharya N.K., Han M., Zavereh S.B., Sedeyn J.C. Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown // Brain Res. 2010; 1345(7): 221-232.

Nagele R.G., Clifford P.M., Siu G., Levin E.C., Acharya N.K. Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-beta‑42 deposition // J. Alzheimers Dis. 2011; In Press.

Gerlach M., Maetzler W., Broich K., Hampel H., Rems L. Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics // J. Neural. Transm. 2011; 5(7): 45-49. In Press.

Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: focus on astrocytes // Mol. Neurobiol. 2013; epub ahead of print.

Sato S., Mizuno Y., Hattori N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease // Neurology. 2005; 64(7): 1081-1083.

Younes-Mhenni S., Frih-Ayed M., Kerkeni A., Bost M., Chazot G. Peripheral blood markers of oxidative stress in Parkinson’s disease // Eur. Neurol. 2007; 58(3): 78-83.

Korff A., Pfeiffer B., Smeyne M., Kocak M., Pfeiffer R.F., Smeyne R.J. Alterations in glutathione S-transferase pi expression follo­wing exposure to MPP+-induced oxidative stress in the blood of Parkinson’s disease patients // Parkinsonism Relat. Disord. 2011; 45(7): 34-45.

Church W.H., Ward V.L. Uric acid is reduced in the substantia nigra in Parkinson’s disease: effect on dopamine oxidation // Brain Res. Bull. 1994; 33(6): 419-425.

Gao X., Chen H., Choi H.K., Curhan G., Schwarzschild M.A., Ascherio A. Diet, urate, and Parkinson’s disease risk in men // Am. J. Epidemiol. 2008; 167(6): 831-838.

Ascherio A., LeWitt P.A., Xu K., Eberly S., Watts A., Matson W.R., Marras C., Kieburtz K., Rudolph A., Bogdanov M.B., Schwid S.R., Tennis M., Tanner C.M., Beal M.F., Lang A.E., Oakes D., Fahn S., Shoulson I., Schwarzschild M.A. Urate as a predictor of the rate of clinical decline in Parkinson disease // Arch. Neurol. 2006; 66(9): 1460-1468.

Waragai M., Wei J., Fujita M., Nakai M., Ho G.J., Masliah E., Akatsu H., Yamada T., Hashimoto M. Increased level of DJ‑1 in the cerebrospinal fluids of sporadic Parkinson’s disease // Biochem. Biophys. Res. Commun. 2006; 345(8): 967-972.

Hong Z., Shi M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Leverenz J.B., Baird G., Montine T.J., Hancock A.M., Hwang H., Pan C., Bradner J., Kang U.J., Jensen P.H., Zhang J. DJ‑1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease // Brain. 2010; 133(3): 713-726.

Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Kim H.M., Leverenz J.B., Montine T.J., Ginghina C., Kang U.J., Cain K.C., Wang Y., Aasly J., Goldstein D., Zhang J. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression // Ann. Neurol. 2011; 69(7): 570-580.

Fеlix J. Jimеnez-Jimenez, Hortensia Alonso-Navarro, Elena Garcia-Martin, Josе A.G. Agundez. Cerebrospinal fluid biochemical studies in patients with Parkinson’s disease: toward a potential search for biomarkers for this disease // Frontiers in Cellular Neuroscience. 2014; 8(369): 1-31.

Moser A., Kömpf D. Presence of methyl‑6,7-dihydroxy‑1,2,3,4-tetrahydroisoquinolines, derivatives of the neurotoxin isoquinoline, in parkinsonian lumbar CSF // Life Sci. 1992; 50(7): 1885-1891.

Matsubara K., Kobayashi S., Kobayashi Y., Yamashita K., Koide H., Hatta M. Beta-Carbolinium cations, endogenous MPP+ analogs, in the lumbar cerebrospinal fluid of patients with Parkinson’s disease // Neurology. 1995; 45(6): 2240-2245.

Jiménez-Jiménez F.J., Molina J.A., Aguilar M.V., Meseguer I., Mateos-Vega C.J., González-Muñoz M.J. Cerebrospinal fluid levels of transition metals in patients with Parkinson’s disease // J. Neural Transm. 1998; 105(6): 497-505.

Mariani S., Ventriglia M., Simonelli I., Donno S., Bucossi S., Vernieri F. Fe and Cu do not differ in Parkinson’s disease: a replication study plus meta-analysis // Neurobiol. Aging. 2013; 34(7): 632-633.

Pålhagen S., Qi H., Mårtensson B., Wålinder J., Granérus A.K., Svenningsson P. Monoamines, BDNF, IL‑6 and corticosterone in CSF in patients with Parkinson’s disease and major depression // J. Neurol. 2010; 257(5): 524-532.

Rota E., Bellone G., Rocca P., Bergamasco B., Emanuelli G., Ferrero P. Increased intrathecal TGF-beta1, but not IL‑12, IFN-gamma and IL‑10 levels in Alzheimer’s disease patients // Neurol. Sci. 2006; 27(4): 33-39.

Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R. Cerebrospinal fluid biomarkers for Parkinson’s disease diagnosis and progression // Ann. Neurol. 2011; 69(8): 570-580.

Mashayekhi F., Mirzajani E., Naji M., Azari M. Expression of insulin-like growth factor‑1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson’s disease // J. Clin. Neurosci. 2010; 17(3): 623-627.

Pankonin M.S., Sohi J., Kamholz J., Loeb J.A. Differential distribution of neuregulin in human brain and spinal fluid // Brain Res. 2009; 1258(6): 1-11.

Ascherio A., LeWitt P.A., Xu K., Eberly S., Watts A., Matson W.R. Urate as a predictor of the rate of clinical decline in Parkinson disease // Arch. Neurol. 2009; 66(8): 1460-1468.

Alonso-Navarro H., Jiménez-Jiménez F.J., García-Martín E., Agùndez J.A.G. Genomic and pharmacogenomic biomarkers of Parkinson’s disease // Curr. Drug Metab. 2014; 15(8): 129-181.

Parnetti L., Chiasserini D., Bellomo G., Giannandrea D., De Carlo C., Qureshi M.M. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson’s disease and degenerative dementias // Mov. Disord. 2011; 26(3): 1428-1435.

Parnetti L., Chiasserini D., Persichetti E., Eusebi P., Varghese S., Qureshi M.M. Cerebrospinal fluid lysosomal enzymes and α-synuclein in Parkinson’s disease // Mov. Disord. 2014а; 29(6): 1019-1027.

Parnetti L., Farotti L., Eusebi P., Chiasserini D., De Carlo C., Giannandrea D. Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson’s Disease // Front. Aging Neurosci. 2014b; 6(8): 53-55.

Compta Y., Martí M.J., Ibarretxe-Bilbao N., Junqué C., Valldeoriola F., Muñoz E. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson’s disease // Mov. Disord. 2009b; 24(7): 2203-2210.

Аlves G., Brønnick K., Aarsland D., Blennow K., Zetterberg H., Ballard C. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson’s disease: the Norwegian ParkWest study // J. Neurol. Neurosurg. Psychiatry. 2010; 81(6): 1080-1086.

Montine T.J., Shi M., Quinn J.F., Peskind E.R., Craft S., Ginghina C. CSF Aβ(42) and tau in Parkinson’s disease with cognitive impairment // Mov. Disord. 2010; 25(7): 2682-2685.

Tokuda T., Salem S.A., Allsop D., Mizuno T., Nakagawa М., Qureshi M.M. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease // Biochem. Biophys. Res. Commun. 2006; 349(7): 162-166.

Hong Z., Shi M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D. DJ‑1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease // Brain 2010; 133(7): 713-726.

Mollenhauer B., Trautmann E., Taylor P., Manninger P., Sixel-Döring F., Ebentheuer J. Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects // Neurosci. Lett. 2013; 532(6): 44-48.

Mollenhauer B., Trenkwalder C., von Ahsen N., Bibl M., Stei­nacker P., Brechlin P. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson’s disease dementia // Dement. Geriatr. Cogn. Disord. 2006; 22(2): 200-208.

Kang J.H., Irwin D.J., Chen-Plotkin A.S., Siderowf A., Caspell C., Coffey C.S. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease // JAMA Neurol. 2013; 70(7): 1277-1287.

Wang Y., Shi M., Chung K.A., Zabetian C.P., Leverenz J.B., Berg D. Phosphorylated α-synuclein in Parkinson’s disease // Sci. Transl. Med. 2012; 4(9): 121-130.

Mondello S., Constantinescu R., Zetterberg H., Andreasson U., Holmberg B., Jeromin A. CSF α-synuclein and UCH-L1 levels in Parkinson’s disease and atypical parkinsonian disorders // Parkinsonism Relat. Disord. 2014; 20(5): 382-387.

Wennström M., Surova Y., Hall S., Nilsson C., Minthon L., Boström F. Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy // PLoS ONE. 2013; 8(3): 53-57.

Chahine L.M., Stern M.B., Chen-Plotkin A. Blood-Based Biomarkers for Parkinson’s Disease // NIH Public Access Author Manuscript. 2014; 20(8): 99-103.

Chen-Plotkin A.S., Hu W.T., Siderowf A., Weintraub D., Goldmann Gross R., Hurtig H.I. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease // Ann. Neurol. 2011; 69(7): 655-663. [PubMed: 21520231].

Pellecchia M.T., Santangelo G., Picillo M., Pivonello R., Longo K., Pivonello C. Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson’s disease patients // J. Neurol. 2013; 260(4): 438-444. [PubMed: 22911513]

Qiang J.K., Wong Y.C., Siderowf A., Hurtig H.I., Xie S.X., Lee V.M. Plasma apolipoprotein A1 as a biomarker for parkinson’s di­sease // Ann. Neurol. 2013; 27(2): 34-37.

McGeer P.L., McGeer E.G. Inflammation and neurodegeneration in Parkinson’s disease // Parkinsonism Relat. Disord. 2004; 23(1): 3-7. [PubMed: 15109580]

Chen H., O’Reilly E.J., Schwarzschild M.A., Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson’s disease // Am. J. Epidemiol. 2008; 167(7): 90-95. [PubMed: 17890755]

Chen H., O’Reilly E.J., Schwarzschild M.A., Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson’s disease // Am. J. Epidemiol. 2008; 167(8): 90-98. [PubMed: 17890755]

Del Tredici K., Hawkes C.H., Ghebremedhin E., Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease // Acta Neuropathol. 2010; 119(8): 703-713.

Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Kim H.M., Leverenz J.B., Montine T.J., Ginghina C., Kang U.J., Cain K.C., Wang Y., Aasly J., Goldstein D., Zhang J. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression // Ann. Neurol. 2011; 69(11): 570-580.




Copyright (c) 2016 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта